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An ongoing challenge for the clinical cardiologist remains
the choice of optimal reperfusion therapy for patients with
ST-segment elevation acute myocardial infarction
(STEMI) who present to community hospitals without
on-site primary percutaneous coronary intervention (PCI).
Numerous studies have demonstrated a clear superiority of
primary PCI over pharmacologic thrombolysis for the treat-
ment of STEMI, with higher initial reperfusion rates,
improved event-free survival, and a lower incidence of
intracranial bleeds (1,2). However,25% of hospitals in the
U.S. and 10% of centers in Europe have the capability of
performing emergency PCI (3). As a result, referral of
STEMI patients for PCI is usually associated with a
significant time delay necessitated by the need for rapid
transport to a tertiary center and the mobilization of
appropriate resources.
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The importance of determining optimal reperfusion in
the community hospital setting is underscored by the shear
number of involved patients and by recent data describing
the timing of mechanical recanalization. Given the current
practice of transporting patients to the nearest hospital for
chest pain evaluation, over 50% of STEMI patients are
initially evaluated in hospitals without on-site PCI capabil-
ity (4). Despite the American College of Cardiology/
American Heart Association (ACC/AHA)-recommended
door-to-balloon times of 90  30 min (3), data on patients
treated with PCI in the National Registry of Myocardial
Infarction (NRMI) indicate a median treatment time delay
of 2 h in 87% of patients transferred for mechanical
intervention (5).
Several recent studies have continued to demonstrate
improved clinical outcomes with primary PCI compared
with pharmacologic reperfusion, even for patients who need
to be transferred to a tertiary center for catheter-based
therapy. In the Danish Multicentre Randomized Trial on
Thrombolytic Treatment Versus Acute Coronary Angio-
plasty in Acute Myocardial Infarction (DANAMI-2) study,
community STEMI patients transferred to a tertiary hos-
pital for primary PCI had a lower composite incidence of
death, recurrent infarction, or stroke at 30 days, compared
with patients receiving on-site thrombolytic therapy (8.5%
vs. 14.2%, p  0.002) (6). Similarly, in the Primary
Angioplasty in Patients Transferred From General Com-
munity Hospitals to Specialised PTCA Units With or
Without Emergency Thrombolysis (PRAGUE) study,
there was an 8% rate of death, myocardial infarction (MI),
or stroke at 30 days in community hospital patients trans-
ferred for primary PCI, compared with 23% for on-site
thrombolysis alone and 15% for patients treated with both
thrombolysis and primary PCI (p 0.02) (7). Finally, in the
Air Primary Angioplasty in Myocardial Infarction (AIR-
PAMI) study, there was a 38% reduction in the 30-day
composite incidence of death, MI, or stroke in patients
emergently transferred for PCI versus on-site thrombolysis
(8.4% vs. 13.6%, p  0.331). Although this difference in
outcome was not significant, a secondary, prespecified
analysis using step-down, multivariate, logistic regression
demonstrated that the strategy of transfer for primary PCI
was independently associated with a reduction in the pri-
mary end point (odds ratio 0.159, p  0.028) (8).
Despite the continued superiority of mechanical interven-
tion even in the setting of interhospital transfer, it is clear
that a prolonged delay in achieving reperfusion in the infarct
vessel has deleterious results. Ample data drawn from
multiple fibrinolytic studies have previously demonstrated
that the time from symptom onset to infarct vessel recana-
lization is an important independent predictor of myocardial
salvage and survival (9–11). Although the limited number
of STEMI patients studied in PCI trials has hindered a
similar assessment of the impact of reperfusion timing, a
recent analysis of 27,000 PCI patients in the NRMI registry
demonstrated that a door-to-balloon time 2 h was asso-
ciated with a 41% to 62% increase in mortality, compared
with patients with shorter intervention times (4).
Another important concept concerning the efficacy of
PCI for STEMI is the observed clinical benefit of achieving
Thrombolysis In Myocardial Infarction (TIMI) flow grade
3 in the infarct vessel before mechanical intervention. In a
recent study combining data on over 2,500 patients from
four PAMI trials, clinical outcomes were compared in
patients who had achieved TIMI flow grade 3 spontane-
ously before PCI with patients who presented with TIMI
flow grade 0, 1, or 2. Consistent with data on the impact of
reperfusion times, patients with spontaneous pre-PCI
TIMI flow grade 3 had a lower mortality, improved left
ventricular function, and lower rates of congestive heart
failure. However, patients with TIMI flow grade 3 also had
higher procedural success rates, with higher rates of TIMI
flow 3 after the intervention. The authors theorized that
improved procedural outcomes may have resulted from
decreased thrombotic burden at the intervention site, less
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distal microvascular embolization, and improved lesion
delineation (12).
Given the need to minimize the time of reperfusion and
the paramount importance of TIMI flow grade 3, there have
been several new strategies proposed to improve outcomes
for STEMI patients presenting to the community hospital.
One approach has been to expand PCI capability to acute-
care centers without on-site cardiac surgery backup, thereby
avoiding the inherent time delay associated with interhos-
pital transport. Publication of data from the Atlantic Car-
diovascular Patient Outcomes Research Team (C-PORT)
trial has fostered the current opinion that there should be
increased dissemination of PCI capability at community
hospitals (13). Several investigators have suggested that all
STEMI patients should be treated as “trauma victims,” with
immediate transport only to “cardiac trauma centers” that
offer PCI.
An alternative approach to the increased establishment of
PCI programs has been the resurgent use of “facilitated
PCI” (14). Facilitated PCI involves the adjunctive use of
pharmacotherapy used in combination with mechanical
revascularization to achieve early, complete, and sustained
flow in the infarct-related epicardial artery and in the
infarct-zone microvasculature. Given the universal availabil-
ity of pharmacotherapy, the desired goal of facilitated PCI is
to improve STEMI outcomes by rapidly administering
drugs in the community hospital and during interhospital
transfer in an attempt to induce earlier infarct-vessel and
tissue-level reperfusion while awaiting definitive interven-
tion in the catheterization laboratory. This complementary
approach theoretically combines the strengths of pharma-
cologic and mechanical revascularization, thus shortening
the time to TIMI flow grade 3, providing a better substrate
for PCI, and widening the therapeutic window for beneficial
revascularization. Potential adjunctive drugs that may have a
role in facilitated PCI include full- or partial-dose throm-
bolytics, glycoprotein (GP) IIb/IIIa inhibitors, low-
molecular-weight heparins, direct thrombin inhibitors, and
thienopyridines.
Despite theoretic considerations that optimal reperfusion
might be achieved with complementary pharmacologic and
mechanical approaches, early attempts to combine these
therapies in the STEMI setting were disappointing. The
earliest “facilitated PCI” trials involved combined use of
thrombolytics with balloon angioplasty. Data from the
Thrombolysis and Angioplasty in Myocardial Infarction
(TAMI-1) study, the TIMI-IIa study, and the European
Cooperative Study Group trial all demonstrated that routine
immediate intervention with balloon angioplasty in the
setting of thrombolytic therapy conferred no benefit with
respect to survival or ventricular function and was in fact
associated with higher complications (15–17).
The debate concerning the merits of combined pharma-
cologic and mechanical therapy has been clearly altered by
improvements in fibrinolytic agents, adjunctive antiplatelet
and antithrombin pharmacology, and the refinement of
catheter-based techniques. The development of “bolus
thrombolytics” has provided new a new class of agents with
enhanced fibrin sensitivity, excellent safety and efficacy
profiles, and greater ease of administration, potentially
shortening the time between symptom onset and treatment
(18). Similarly, the combined use of thrombolytics (includ-
ing reduced or half dose) with GP IIb/IIIa inhibitors has
been theorized to engender more stable reperfusion by
potentiating fibrinolysis with platelet disaggregation. Data
from the Global Use of Strategies to Open Occluded
Coronary Arteries V (GUSTO V) (19) and Assessment of
the Safety and Efficacy of a New Thrombolytic Regimens
(ASSENT-3) (20) trials have demonstrated that the speed
and quality of infarct-vessel reperfusion may be increased
with this strategy, with a reduced incidence of recurrent
ischemic events, including in-hospital re-infarction, recur-
rent or refractory ischemia, or urgent PCI. Other agents
that may theoretically provide for more comprehensive clot
lysis with more rapid, complete, and sustained myocardial
perfusion include low-molecular-weight heparins, direct
thrombin inhibitors, and thienopyridines.
Improvements in pharmacologic reperfusion have been
paralleled by simultaneous refinement of mechanical revas-
cularization techniques. Apart from increased operator ex-
perience, advances in catheter design, refinement of heparin
dosing regimens in the catheterization laboratory, and the
development of arteriotomy closure devices, intracoronary
stenting has been shown to be superior to balloon angio-
plasty in STEMI patient with less recurrent ischemia, less
early re-occlusion, and reduced late infarct-vessel restenosis
(21). Mechanical thrombectomy and distal embolization
protection devices are two additional modalities that are
currently being tested and may have a role in the treatment
of STEMI patients.
A critical question which remains is whether the advance-
ments that have occurred separately with pharmacologic or
mechanical reperfusion will result in improvements in safety
and efficacy with the combined use of these therapies. In the
Plasminogen-activator Angioplasty Compatibility Trial
(PACT), STEMI patients treated with combined reduced-
dose tissue-type plasminogen activator (t-PA) and immedi-
ate catheterization with angioplasty, as indicated, had
higher pre-PCI rates of TIMI flow grade 3 in the infarct
vessel compared with patients treated with mechanical
revascularization alone, with no adverse effects of combined
therapy (22). Similarly, in the Strategies for Patency En-
hancement in the Emergency Department (SPEED) trial,
the combined use of reduced-dose reteplase, abciximab, and
urgent catheterization with PCI was not associated with any
increased risk and resulted in the highest rates of TIMI flow
grade 3 on initial angiography, as compared with other
treatment regimens (23). In a more recent study re-
evaluating 1,938 patients from the TIMI-10B and
TIMI-14 trials, the combined use of thrombolysis (with and
without abciximab) with rescue, adjunctive, or delayed PCI
resulted in a lower 30-day composite of death and re-
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infarction, compared with patients with “successful throm-
bolysis” who did not undergo revascularization (24). Finally,
in the Abciximab Before Direct Angioplasty and Stenting in
Myocardial Infarction Regarding Acute and Long-Term
Follow-up (ADMIRAL) trial, the combined use of primary
stenting with abciximab versus stenting with placebo re-
sulted in significant reductions in the composite end point
of death, re-infarction, and urgent target vessel revascular-
ization at both 30 days and 6 months (25).
As another study demonstrating a possible role for
facilitated PCI, Scheller et al. (26) have presented results of
the South West German Interventional Study in Acute
Myocardial Infarction (SIAM III) trial in this issue of the
Journal. Following full-dose thrombolytic therapy, 163
STEMI patients from the community hospital were ran-
domized to either a strategy of transport to a tertiary center
for immediate stenting or delayed stenting two weeks later.
The immediate stenting strategy resulted in a significant
reduction in the six-month combined end point of ischemic
events, death, re-infarction, and target lesion revasculariza-
tion (25.6% vs. 50.6%, p 0.001). This beneficial effect was
mainly driven by a reduction in recurrent ischemic events in
the immediate stenting group (4.9% vs. 28.4%, p  0.01).
On an intention-to-treat basis, immediate stenting was also
associated with a reduction in the six-month combined end
point of death, re-infarction, and target lesion revascular-
ization (27.7% vs. 39.8%, p  0.049). In addition, imme-
diate stenting was associated with improved left ventricular
ejection fraction at two weeks, as well as a further improve-
ment in the ejection fraction at six months.
As a “real-world” reperfusion trial, SIAM III illustrates
many of the problems commonly observed in treating
STEMI patients from the community hospital. The mean
3.2 to 3.6 h “time to thrombolysis” and the mean 6.7 h “time
to angiography” in the immediate stenting group exceed the
optimal door-to-needle and door-to-balloon times currently
recommended. The use of full-dose thrombolytic therapy
without immediate PCI in the delayed stenting group was
associated with an unacceptable 30-day 24.7% incidence of
recurrent ischemic events, a 30-day 12.3% incidence of
death or re-infarction, and a two-week 58.9% incidence of
TIMI flow grade 3 in the infarct vessel. Similarly, the use of
full-dose fibrinolytic therapy in both study arms was asso-
ciated with an unacceptably high 8.6% incidence of major
bleeding, including a 2.4% incidence of stroke. Other
limitations of the study include the relatively low use of GP
IIb/IIIa inhibitors, the use of full-dose thrombolytic therapy
in the setting of cardiogenic shock, and a small, underpow-
ered study size.
Apart from these limitations, however, the SIAM III
study does rekindle ongoing interest in the facilitated PCI
concept. Over 60% of patients in the immediate stenting
group had baseline TIMI flow grade 3 in the infarct vessel
at the time of initial angiography, with a 97.5% incidence of
TIMI flow 3 following the intervention and a 98.6%
incidence at two weeks. Patients in both groups with TIMI
flow grade 2 or 3 before the intervention had improved
ventricular function at two weeks and six months, compared
with patients with TIMI flow grade 0 or 1. Finally, despite
relatively long treatment times, the combined use of full-
dose thrombolytics with transfer for immediate stenting
resulted in a relatively low 4.9% incidence of death and a
7.3% incidence of death or re-infarction at 30 days.
It is clear that more data are needed to determine the
efficacy and safety of the facilitated PCI approach. A true
assessment of this strategy will await the results of ongoing
clinical trials, including among others FINESSE (Facilitat-
ed Intervention with Enhanced Reperfusion Speed to Stop
Events), ADVANCE-MI (Addressing the Value of Facil-
itated Angioplasty After Combination Treatment or Epti-
fibatide Monotherapy in Acute Myocardial Infarction), and
ASSENT-4 PCI. Additional studies will be needed to fully
evaluate the ever-increasing armamentarium of pharmaco-
logic agents and ongoing improvements in mechanical
revascularization. The obvious goal of all of these efforts is
to end the long-standing debate about the relative superi-
ority of pharmacologic over mechanical intervention, so that
we can move forward in an attempt to find an even better
reperfusion option. Such an approach is clearly needed for
all patients, but particularly for the STEMI patient present-
ing to the community hospital without immediate access to
a catheter-based therapy.
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